Synthesis and antiviral activity of 1-O-octadecyl-2-O-alkyl-sn-glycero-3-foscarnet conjugates in human cytomegalovirus-infected cells

Antiviral Research

Volumn 36, Issue 2, 1997, Pages 115-124

  Kini, Ganesh D ^a   Hostetler, Saskia E ^a   Beadle, James R ^a   Aldern, Kathy A ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antiviral agents; Cytomegalovirus; Lipids; Prodrugs; Structure activity relationship

Indexed keywords

ANTIVIRUS AGENT; FOSCARNET; PRODRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG ACTIVITY; ENANTIOMER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RACEMIC MIXTURE; STRUCTURE ACTIVITY RELATION;

ANTIVIRAL AGENTS; CELL LINE; CYTOMEGALOVIRUS; FOSCARNET; HUMANS;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 0030729078     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(97)00048-X     Document Type: Article

References (11)

1. Balfour H.H. Jr., Fletcher C.V., Erice A., Henry W.K., Acosta E.P., Smith S.A., Holm M.A., Boivin G., Shepp D.H., Crumpacker C.S., Eaton C.A., Martin-Munley S.S. Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. Antimicrob. Agents Chemother. 40:1996;2721-2726.
2. Beadle, J.R., Kini, G.D., Aldern, K.A., Gardner, M.F., Wright, K.N., Richman, D.D., Hostetler, K.Y., 1997. Alkylthioglycerol prodrugs of foscarnet: Synthesis. Oral bioavailability and structure-activity studies in HCMV, HSV-1 and HIV-1 infected cells. Antiviral Chem. Chemother. (in press).
3. Blanshard C., Benhamou Y., Dohin E., Lernestedt J.O., Gazzard B.G., Katlama C. Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison. J. Infect. Dis. 172:1995;622-628.
4. Chrisp P., Clissold S.P. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs. 41:1991;104-129.
5. Holland G.N., Levinson R.D., Jacobson M.A. Dose-related difference in progression rates of cytomegalovirus retinopathy during foscarnet maintenance therapy. AIDS Clinical Trials Group Protocol 915 Team. Am. J. Ophthalmol. 119:1995;576-586.
6. Hostetler K.Y., Kini G.D., Beadle J.R., Aldern K.A., Gardner M.F., Border R., Kumar R., Barshak L., Sridhar C.N., Wheeler C.J., Richman D.D. Lipid prodrugs of phosphonoacids: greatly enhanced antiviral activity of 1-O-octadecyl-sn-glycero-3-phosphonoformate in HIV-1, HSV-1 and HCMV-infected cells, in vitro. Antiviral Res. 31:1996;59-67.
7. Jabs D.A. Foscarnet-ganciclovir cytomegalovirus retinitis trial. 4. Visual outcomes. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Ophthalmology. 101:1994;1250-1261.
8. Jacobson M.A., Wulfsohn M., Feinberg J.E., Davis R., Power M., Owens S., Causey D., Heath-Chiozzi M.E., Murphy R.L., Cheung T.W., Dieterich D.T., Spector S.A., McKinley G.F., Parenti D.M., Crumpacker C. and the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG protocol 093). AIDS clinical trials group of the National Institute of Allergy and Infectious Diseases. AIDS. 8:1994;451-459.
9. Kaiser L., Perrin L., Hirschel B., Furrer H., Von Overbeck J., Olmari M., Yerly S. Foscarnet decreases human immunodeficiency virus RNA. J. Infect. Dis. 172:1995;225-227.
10. Kini G.D., Beadle J.R., Xie H., Aldern K.A., Richman D.D., Hostetler K.Y. Alkoxypropane prodrugs of foscarnet: effect of alkyl chain length on in vitro antiviral activity in cells infected with HIV-1, HSV-1 and HCMV. Antiviral Res. 36:1997;43-53.
11. Polis M.A., deSmet M.D., Baird B.F., Mellow S., Falloon J., Davey R.T. Jr., Kovacs J.A., Palestine A.G., Nussenblatt R.B., Masur H., Lane H.C. Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). Am. J. Med. 94:1993;175-180.